Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

July 4, 2012

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies.

About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although is an option for some, patients without a matched donor have few treatment options. The findings of this new clinical study, carried out by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, suggest eltrombopag could be a second-line for them.

"Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia," will be published online July 5 in the .

Aplastic anemia is a rare blood disorder, with about 600 new cases in the U.S. each year. Aplastic anemia results from the destruction of bone marrow stem cells, which mature into that carry oxygen, that fight infection, and platelets that prevent excess bleeding. Symptoms of the disorder include fatigue, frequent infections, and hemorrhaging. In severe cases unresponsive to treatment, death can occur.

Eleven of 25 participants enrolled in this phase 2 study showed improved production of at least one type of blood cell (red blood cell, white blood cell, or platelet) after 12 weeks of oral eltrombopag therapy. Among the seven volunteers who continued taking the pills long-term (8-32 months), six eventually showed an improvement in all three types of blood cells, and were able to maintain safe blood counts without needing red blood cell or platelet transfusions. Overall the drug was well tolerated, with few side effects.

The research team in the NHLBI Hematology Branch tested eltrombopag because this drug had previously been shown to boost platelet levels in both healthy people and people with reduced platelets due to hepatitis C infection or immune thrombocytopenia, blood disorders that like aplastic anemia result in low platelet counts and increased risk of bleeding.

The encouraging finding in this study was improvement in red blood cell and white cell counts in some aplastic anemia patients, suggesting that the drug can stimulate bone marrow stem cells and perhaps have wider utility than initially predicted.

Explore further: Standard aplastic anemia therapy improves patient outcomes better than newer version

More information: Learn more about this study at: clinicaltrials.gov/ct2/show/NCT00922883
Learn more about aplastic anemia at: www.nhlbi.nih.gov/health/healt … ics/topics/aplastic/

Related Stories

Standard aplastic anemia therapy improves patient outcomes better than newer version

August 4, 2011
A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than did Thymoglobulin, ...

The Medical Minute: What is myelodysplastic syndrome?

June 15, 2012
Television journalist and host of "Good Morning America" Robin Roberts announced this week that she has myelodysplastic syndrome, or MDS, an uncommon blood and bone marrow disorder.

Omontys approved for anemic people with kidney disease

March 27, 2012
(HealthDay) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.

Recommended for you

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.